Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.58
- Piotroski Score 4.00
- Grade Equal-Weight
- Symbol (CTLT)
- Company Catalent, Inc.
- Price $60.97
- Changes Percentage (2.2%)
- Change $1.31
- Day Low $59.82
- Day High $61.50
- Year High $61.50
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/07/2025
- Fiscal Year End N/A
- Average Stock Price Target $63.50
- High Stock Price Target $132.00
- Low Stock Price Target $41.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.48
- Trailing P/E Ratio -8.7
- Forward P/E Ratio -8.7
- P/E Growth -8.7
- Net Income $-1,043,000,000
Income Statement
Quarterly
Annual
Latest News of CTLT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Catalent, Inc. (CTLT) Stock Price, News, Quote & History
Five U.S. consumer groups and two labor unions are urging the FTC to block Novo Holdings' acquisition of Catalent, citing concerns about competition in weight loss drugs and gene therapies. The $16.5 ...
By Yahoo! Finance | 1 month ago -
Decoding Catalent Inc (CTLT): A Strategic SWOT Insight
Catalent Inc faces challenges like intense competition and regulatory changes affecting cell and gene therapies. Despite financial setbacks, the company's strengths include biologics segment growth an...
By Yahoo! Finance | 2 months ago -
Should You Invest In Catalent, Inc. (CTLT) Right Now?
Elliott Management's top 10 stock picks include Catalent, Inc. The hedge fund, known for its activist campaigns, has seen success with a 4.7% gain in 2023....
By Yahoo! Finance | 3 months ago
